Table I.
Target antigens for ADCs in preclinical and clinical development | |
---|---|
Cancer | Target antigens |
Breast | CD174, GPNMB, CRIPTO and nectin-4 (ASG-22ME) |
Ovarian | MUC16 (CA125), TIM-1 (CDX-014) and mesothelin |
Lung | CD56, CD326, CRIPTO, FAP, mesothelin and GD2 |
Pancreatic | CD74, CD227 (MUC-1) and nectin-4 (ASG-22ME) |
Prostate | PSMA, STEAP-1 and TENB2 |